The approval marks a major milestone for the company and represents an important validation of its technology platform, it states.

“This is a highly significant achievement for Mucocort AB. Receiving our first approved patent in the US validates both the medical utility and innovation behind our technology and the long-term commercial potential of M045A. The United States is one of the world’s most important healthcare markets, and this approval gives us a strong strategic foundation for a future market launch of our product,” says Jean Lycke, Project Manager at Mucocort.

The newly approved U.S. patent protects Mucocort’s proprietary technology and strengthens the company’s position ahead of future partnering, licensing, and commercialization discussions.